Advancing Cancer Management: The Dual Diagnostic-Prognostic Potential of Nucleic Acid Biomarkers

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Cancer early detection is critical for survival but current methods like imaging and biopsy have limitations.
• Nucleic acid biomarkers, including epigenetic markers (DNA methylation, non-coding RNA), are crucial for cancer diagnosis, prognosis, and monitoring.
• Liquid biopsy, using circulating tumor DNA (ctDNA), offers non-invasive monitoring but faces sensitivity and cost challenges.

Purpose of the Study:

• To review the role of cancer nucleic acid markers in diagnosis and prognosis.
• To examine the molecular mechanisms, advantages, and limitations of these biomarkers.
• To discuss tumor microenvironment and immune response biomarkers and their nucleic acid interactions.

Main Methods:

• Literature review of nucleic acid biomarkers in cancer.
• Analysis of molecular mechanisms of epigenetic and circulating tumor DNA markers.
• Evaluation of multimodal strategies combining different biomarker approaches.

Main Results:

• Nucleic acid biomarkers, particularly ctDNA methylation, show promise for accurate and non-invasive cancer detection and prognosis.
• Combining ctDNA methylation with other nucleic acid markers or multimodal strategies can enhance specificity and overcome individual technique limitations.
• Biomarkers related to the tumor microenvironment and immune response are increasingly important in understanding cancer progression.

Conclusions:

• Nucleic acid biomarkers represent a significant advancement in oncology for early cancer detection, prognosis, and monitoring.
• Multimodal strategies integrating various nucleic acid markers are essential for improving diagnostic accuracy and overcoming current limitations.
• Further research into tumor microenvironment and immune-related nucleic acid biomarkers will refine cancer management strategies.